Avinger, Inc. Announces Participation in Canaccord Genuity 36th Annual Growth Conference

REDWOOD CITY, Calif., Aug. 09, 2016 -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company plans to participate in the Canaccord Genuity 36th Annual Growth Conference in Boston.

Avinger management is scheduled to present on Wednesday, August 10, 2016 at 1:00pm ET. Interested parties can access the live audio webcast with accompanying slides from the Events section of Avinger’s website at www.avinger.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.

About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the legs and feet. The company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its Lumivascular Platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current Lumivascular products include the Lightbox™ imaging console, the Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit www.avinger.com.

“Avinger,” “Lumivascular,” “Lightbox,” “Ocelot,” “Pantheris” and the Avinger logo are registered trademarks of Avinger, Inc.

Investor Contact:
Matt Ferguson
Avinger, Inc.
(650) 241-7917
[email protected]